The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

HHS Secretary Robert F. Kennedy Jr named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates ... funded in part by the US Department of Health and Human Services Biomedical Advanced Research and ...